Biohaven

Biohaven is a modern pharmaceutical company that is guided by science and inspired to change the lives of people with unmet medical needs.

[Biohaven @biohaven]

Our annual Research & Development Day brought together our leadership team, industry experts and investors to share the latest on Biohaven’s pipeline progress in immunology, epilepsy, obesity and more. View the presentation here: https://t.co/ZNOZlAdLL1
#DaysMatter
#Investors

[Biohaven @biohaven]

Biohaven is heading to the @ERAkidney Congress with a booth highlighting our TRAP™ degrader. Come stop by, say hello to our team and learn more about our work in kidney disease: https://t.co/jO2afyZeed
#ERA26
#DaysMatter
#IgAN
#KidneyDisease
#MedEd

[Biohaven @biohaven]

Connecticut innovation was front and center at the Yale Innovation Summit! Our CEO joined healthcare leaders for a panel discussion on building and scaling companies within Connecticut’s growing biotech ecosystem.
#YaleInnovationSummit
#Connecticut
#Biotech
#DaysMatter

[Biohaven @biohaven]

We look forward to connecting with peers across the ecosystem at the Yale Innovation Summit and advancing conversations that help bring new scientific breakthroughs closer to patients. Join us: https://t.co/hzpLFwZelD
#YaleInnovationSummit
#Biotech
#Innovation

[Biohaven @biohaven]

Purpose and empathy help drive scientific innovation. Shodeinde Coker, M.D. shares his oncology journey and commitment to advancing new treatments for people facing cancer. Read more: https://t.co/XVsJLx4D5C #DaysMatter #Oncology #ADCs

[Biohaven @biohaven]

Biohaven is featured in the news for our differentiated approach to obesity treatment — one focused not just on weight loss, but on improving body composition by targeting fat reduction while building muscle. Read more about our experimental program: https://t.co/UZI8cNqKgq

[Biohaven @biohaven]

#Investors: Our Chief Medical Officer and SVP of Finance will participate in a fireside chat at the Bank of America Global Healthcare Conference, sharing insights on our pipeline developments.
#DaysMatter
#Innovation
#Pipeline

[Biohaven @biohaven]

In his recent article, Brian McGuire, M.D., shares how his experience in emergency medicine continues to shape his work in drug development and his commitment to helping patients. Read more: https://t.co/PJx4yFjh38
#ThoughtLeadership
#DaysMatter
#PrecisionMedicine

[Biohaven @biohaven]

We loved connecting with clinicians, researchers and advocates at #AAN2026 who share our mission: advancing science to improve patient outcomes.
#DaysMatter
#Neuroscience
#Epilepsy
#ParkinsonsDisease

[Biohaven @biohaven]

Stop by our booth at #AAN2026 to meet our team, learn about our pipeline and see how we’re advancing science to improve patient outcomes.
#DaysMatter
#Neuroscience
#Epilepsy
#ParkinsonsDisease
#Degraders

[Biohaven @biohaven]

Congratulations to our CEO on being named the 2026 Howard Zonana Prize recipient by the @YaleMed Law and Psychiatry Division! This honors an alumnus of Yale’s forensic psychiatry fellowship who has made outstanding contributions to psychiatry as a clinician, educator and scholar.

[Biohaven @biohaven]

Our CMO, Oncology will join leaders at the Chief Medical Officer Summit 360 to discuss how AI can help optimize clinical trials and accelerate insights across drug development. Meet us there: https://t.co/A64kJz9dTe
#CMO360
#ClinicalDevelopment
#AI
#DrugDevelopment

[Biohaven @biohaven]

We’re sharing preclinical data on our MoDE™ degrader in pemphigus vulgaris, a rare autoimmune skin disease, at the upcoming @AADmember Annual Meeting. Register here: https://t.co/E5ZIKHHAQg
#AAD2026
#MedEd
#DaysMatter

[Biohaven @biohaven]

The @MichaelJFoxOrg Foundation is hosting its Parkinson’s IQ + You event in Nevada this weekend and our Chief Medical Officer will be speaking on the panel, “Exploring the Latest in Parkinson’s Research”, to share his perspective on the evolving landscape: https://t.co/hvEa4huup9

[Biohaven @biohaven]

Our CEO will join industry leaders at the R&D Leadership Summit for a discussion on how the industry can drive innovation and deliver transformative medicines balancing large-scale therapeutic opportunities with the growing potential of precision science: https://t.co/xAz78vYgrj

[Biohaven @biohaven]

Our CEO will be participating in the @Yale Entrepreneurial Society Dinner this week, where he will share his journey through academic medicine, biotech entrepreneurship and the founding of Biohaven.
#Yale
#Entrepreneurship

[Biohaven @biohaven]

Our Chief Translational Officer is presenting at the TD Cowen Health Care Conference sharing an update on our pipeline and the platform technologies driving it including our degrader, ion channel, oncology and myostatin programs.
#DaysMatter
#Investors
#TDcowenHealthcare

[Biohaven @biohaven]

The @US_FDA is hosting its virtual #RareDiseaseDay. The event will highlight their initiatives to advance medical product development for rare diseases, the use of real-world data and more. Patients, families, HCPs and advocates are encouraged to attend: https://t.co/r6TQMF71KE

[Biohaven @biohaven]

Biohaven’s oncology leadership team will be participating in a fireside chat at @Citi’s 2026 Virtual Oncology Leadership Summit! We look forward to engaging with the community and contributing to the broader dialogue shaping the future of oncology.
#DaysMatter
#Oncology

[Biohaven @biohaven]

The Clinical Research Center at @UConnHealth is among several clinical sites participating in our global trial evaluating an investigational therapy designed to target the root cause of IgA nephropathy, a rare kidney disease. Learn more about the study: https://t.co/7tBJyRmNRC